A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of Texas MD Anderson Cancer Center demonstrated significantly increased progression-free survival in multiple myeloma patients.
The study, which followed 202 patients, compared busulfan with melphalan versus melphalan alone. Progression-free survival was 65 months for patients receiving combination...
Unresectable pancreatic cancer is usually fatal because other treatments, such as radiation therapy, cannot be used. Radiation therapy causes...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of Texas...
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income pregnant women, there are few areas related to cancer prevention, treatment or research untouched by the funding received by MD Anderson from the Cancer Prevention and Research Institute of Texas (CPRIT).
MD Anderson and its projects have been fortunate to have received $447.6 million, or...
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months...
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...